Menu
You have to log in or sign up before you can proceed.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€7.69

€7.69

-4.250%
-0.346
-4.250%
€26.70
 
12.12.25 / Tradegate WKN: A2AG6H / Symbol: NTLA / Name: Intellia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Intellia

sharewise wants to provide you with the best news and tools for Intellia, so we directly link to the best financial data sources.

News

2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street: https://g.foolcdn.com/editorial/images/838880/person-raising-two-fists-in-the-air.jpg
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street

The "Magnificent Seven" stocks, a group of (mostly) tech giants, are among the most covered companies on Wall Street. The general sentiment about these corporations is that they boast attractive

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%: https://g.foolcdn.com/editorial/images/838660/scientist-altering-dna-genome-project.jpg
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

Intellia Therapeutics (NASDAQ: NTLA), a small-cap biotech company, has some notable bulls. One of them is Cathie Wood, the CEO of Ark Invest. The innovation-focused investment firm has long held

1 Stock Up by 63% This Year That Could Double, According to Wall Street: https://g.foolcdn.com/editorial/images/835831/scientist-altering-dna-genome-project.jpg
1 Stock Up by 63% This Year That Could Double, According to Wall Street

Shares of Intellia Therapeutics (NASDAQ: NTLA), a small-cap biotech company, are up by 63% this year. The company is benefiting from substantial clinical progress, and judging by price targets set

Intellia (NTLA) Q2 Revenue Jumps 106%
Intellia (NTLA) Q2 Revenue Jumps 106%

Intellia Therapeutics (NASDAQ:NTLA), a biotechnology company developing CRISPR-based gene-editing therapies, reported second quarter 2025 results on August 7, 2025. The headline news was a